Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX – Get Free Report) shares shot up 3.7% during trading on Wednesday . The company traded as high as $0.28 and last traded at $0.28. 13,936 shares traded hands during trading, a decline of 93% from the average session volume of 201,218 shares. The stock had previously closed at $0.27.
Virpax Pharmaceuticals Stock Performance
The business has a fifty day simple moving average of $0.25 and a two-hundred day simple moving average of $4.25.
Virpax Pharmaceuticals Company Profile
Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
Featured Articles
- Five stocks we like better than Virpax Pharmaceuticals
- What is the S&P 500 and How It is Distinct from Other Indexes
- Chime’s Smart IPO: Half the Valuation, Double the Strength
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks
- How to Most Effectively Use the MarketBeat Earnings Screener
- 3 Catalysts in 7 Days: Archer’s Growth Story Just Accelerated
Receive News & Ratings for Virpax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virpax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
